BioIVT, LLC

BioIVT, LLC is a provider of high-quality human and animal biospecimens, supporting research and development in drug discovery and development across various scientific disciplines. Founded in 1981, BioIVT, LLC specializes in the supply of biospecimens for research purposes. The company underwent a recapitalization in October 2021 when Linden and Arsenal Capital Partners acquired a majority stake from Thompson Street Capital Partners. BioIVT is based in the US and is led by co-CEOs Kevin King and Richard Thorp, who bring extensive experience in the biotechnology sector.

BioIVT specializes in the provision of high-quality human and animal biospecimens, which are integral to advancing research in various scientific fields, particularly drug discovery and development. Their core product offerings include a diverse array of biofluids such as whole blood, plasma, and serum, as well as primary cells, cell lines, and molecular products, which encompass DNA, RNA, and other tissue extractions. These biospecimens serve a critical role in research and clinical applications, aiding researchers in studying drug metabolism, drug-drug interactions, and other vital areas of pharmaceutical science. The company’s services are tailored to meet specific client needs, facilitating customization of samples to align with ongoing research projects.

BioIVT's client base spans globally across North America, Europe, Asia Pacific, the Middle East, and Africa, catering primarily to pharmaceutical companies, academic institutions, and research organizations seeking reliable and high-quality biological materials. BioIVT employs a structured transaction model aimed at business-to-business (B2B) engagements with various clients in the pharmaceutical and research sectors. Revenue is primarily generated through direct sales of its biospecimens and related services, which include bioanalysis, biospecimen characterization, and specialized assay programs. Clients typically engage with BioIVT through one-time purchases or ongoing service agreements, as they often require consistent access to specific biospecimens for their research needs.

The company offers a proprietary product, ELEVATING SCIENCE®, which emphasizes its commitment to providing exceptional biospecimen quality and service reliability. Pricing structures for individual products are customized based on the specifications and requirements outlined by clients, ensuring that BioIVT meets the unique demands of its diverse clientele. The recapitalization in October 2021 will further enhance BioIVT's growth plans and accelerate the development of its solutions to continuously meet the needs and demands of clients in the biotechnology and life sciences industry. The company is focused on expanding its product offerings and plans to introduce new biospecimen types by 2023.

Furthermore, BioIVT is looking to increase its market presence in Europe and Asia, targeting specific regions for expansion by 2024. The recent funding will be utilized to support these initiatives and ensure the company can effectively cater to the evolving requirements of its clients.